Lapatinib ditosylate hydrate is a tyrosine kinase inhibitor belonging to the quinazoline class, indicated for use in combination therapy for the treatment of patients with advanced or metastatic HER2-positive… Read more
Lapatinib ditosylate hydrate is a tyrosine kinase inhibitor belonging to the quinazoline class, indicated for use in combination therapy for the treatment of patients with advanced or metastatic HER2-positive breast cancer. To ensure the safety and efficacy of this therapeutic agent, pharmaceutical laboratories require access to precise reference standards for rigorous quality control. This category provides an extensive range of related materials, including identified impurities, degradation products, and metabolites that are essential for accurate impurity profiling and method validation during pharmaceutical development. Additionally, the inclusion of stable isotope labelled compounds offers researchers the high-precision tools necessary for consistent quantification in complex bioanalytical assays. These analytical materials support the stringent demands of pharmaceutical testing throughout the drug development lifecycle, ensuring that manufacturing processes consistently meet the required quality specifications for this critical oncology medication.
